Enlicitide vs Laroprovstat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Enlicitide · Lipfendra

Marketed by Merck & Co.

Phase 3 in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT05952856 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 2,909 adults with hypercholesterolemia. The primary endpoint was the mean percent change in LDL-C from baseline to Week 24, a standard regulator-accepted efficacy measure for lipid-lowering therapy. The active arm achieved a significantly greater LDL-C reduction than placebo (-57.1% vs +3.0%, p<0.001), so the trial met its primary endpoint with a large effect size and low risk of bias.

Next expected readout: November 2027 · NCT07821944 (registry estimate)

Reported efficacy

Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24); Number of Participants With One or More Adverse Events (AEs) (Up to 60 weeks); Number of Participants Who Discontinued Study Drug Due to an AE (Up to 52 weeks): Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). (met)

Result source: NCT05952856

Laroprovstat

Developed by AstraZeneca

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Reliable signal

NCT06173570 · Phase 2 · completed

The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).

Next expected readout: January 2027 · NCT07000136 (registry estimate)

Reported efficacy

Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)

Result source: NCT06173570

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnlicitideLaroprovstat
LDL-C, % change-58.2% vs 2.6%−60.8 vs placebowk 24 · n 198NCT05952869
6 other results
  • -64.6% vs -36.5% wk 8 · n 101 · Phase 3 · primary NCT06450366
  • -55.3% vs 8.7% wk 52 · n 193 · Phase 3 · secondary NCT05952869
  • -59.7% vs 1.2% 30 mg · wk 8 · n 73 · Phase 2 · primary NCT05261126
  • -57.9% vs 1.2% 18 mg · wk 8 · n 74 · Phase 2 · primary NCT05261126
  • -54.5% vs 1.2% 12 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
  • -40% vs 1.2% 6 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
-46.6% vs 4.1%−50.7 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.1% vs 4.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT06173570
  • -33.8% vs 4.1% 3 mg · wk 12 · n 85 · Phase 2 · primary NCT06173570
  • -31.2% vs 4.1% 1 mg · wk 12 · n 86 · Phase 2 · primary NCT06173570
  • -46.4% vs 3.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -40.5% vs 3.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.4% vs 3.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -30.5% vs 3.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Non-HDL-C, % change-52.3% vs 2.1%−54.4 vs placebowk 24 · n 198NCT05952869
5 other results
  • -58% vs -31.8% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -54.3% vs 1.5% 30 mg · wk 8 · n 73 · Phase 2 · secondary NCT05261126
  • -51.8% vs 1.5% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -49% vs 1.5% 12 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
  • -34.4% vs 1.5% 6 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
-41.6% vs 3.5%−45.2 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.4% vs 2.9% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -35.1% vs 3.5% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -34.8% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -29.9% vs 3.5% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -29.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -26.9% vs 3.5% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -26.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
ApoB, % change-48.2% vs 1.8%−50 vs placebowk 24 · n 197NCT05952869
5 other results
  • -54.6% vs -27.7% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -51.8% vs 0% 30 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -48.7% vs 0% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -45.8% vs 0% 12 mg · wk 8 · n 75 · Phase 2 · secondary NCT05261126
  • -32.8% vs 0% 6 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
-37.0% vs 2.9%−39.9 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -36.9% vs 2.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -34.3% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.9% vs 2.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -25.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.5% vs 2.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -23.4% vs 2.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Lp(a), % change-24.7% vs -1.6%−23.1 vs placebowk 24 · n 196NCT05952869
1 other result
  • -26.2% vs 10.4% wk 8 · n 101 · Phase 3 · secondary NCT06450366
-19.4% vs 0%−19.4 vs placebo30 mg · wk 12 · n 76NCT06173570
3 other results
  • -19.6% vs 0% 10 mg · wk 12 · n 81 · Phase 2 · secondary NCT06173570
  • -11.2% vs 0% 3 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
  • -7.5% vs 0% 1 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
3-point MACE (% with event)—Not posted · NCT07216482—Trial running · NCT06834932

LDL-C, % change

Enlicitide
-58.2% vs 2.6%−60.8 vs placebowk 24 · n 198NCT05952869
6 other results
  • -64.6% vs -36.5% wk 8 · n 101 · Phase 3 · primary NCT06450366
  • -55.3% vs 8.7% wk 52 · n 193 · Phase 3 · secondary NCT05952869
  • -59.7% vs 1.2% 30 mg · wk 8 · n 73 · Phase 2 · primary NCT05261126
  • -57.9% vs 1.2% 18 mg · wk 8 · n 74 · Phase 2 · primary NCT05261126
  • -54.5% vs 1.2% 12 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
  • -40% vs 1.2% 6 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
Laroprovstat
-46.6% vs 4.1%−50.7 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.1% vs 4.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT06173570
  • -33.8% vs 4.1% 3 mg · wk 12 · n 85 · Phase 2 · primary NCT06173570
  • -31.2% vs 4.1% 1 mg · wk 12 · n 86 · Phase 2 · primary NCT06173570
  • -46.4% vs 3.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -40.5% vs 3.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.4% vs 3.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -30.5% vs 3.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

Non-HDL-C, % change

Enlicitide
-52.3% vs 2.1%−54.4 vs placebowk 24 · n 198NCT05952869
5 other results
  • -58% vs -31.8% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -54.3% vs 1.5% 30 mg · wk 8 · n 73 · Phase 2 · secondary NCT05261126
  • -51.8% vs 1.5% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -49% vs 1.5% 12 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
  • -34.4% vs 1.5% 6 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
Laroprovstat
-41.6% vs 3.5%−45.2 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.4% vs 2.9% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -35.1% vs 3.5% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -34.8% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -29.9% vs 3.5% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -29.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -26.9% vs 3.5% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -26.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

ApoB, % change

Enlicitide
-48.2% vs 1.8%−50 vs placebowk 24 · n 197NCT05952869
5 other results
  • -54.6% vs -27.7% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -51.8% vs 0% 30 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -48.7% vs 0% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -45.8% vs 0% 12 mg · wk 8 · n 75 · Phase 2 · secondary NCT05261126
  • -32.8% vs 0% 6 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
Laroprovstat
-37.0% vs 2.9%−39.9 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -36.9% vs 2.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -34.3% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.9% vs 2.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -25.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.5% vs 2.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -23.4% vs 2.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

Lp(a), % change

Enlicitide
-24.7% vs -1.6%−23.1 vs placebowk 24 · n 196NCT05952869
1 other result
  • -26.2% vs 10.4% wk 8 · n 101 · Phase 3 · secondary NCT06450366
Laroprovstat
-19.4% vs 0%−19.4 vs placebo30 mg · wk 12 · n 76NCT06173570
3 other results
  • -19.6% vs 0% 10 mg · wk 12 · n 81 · Phase 2 · secondary NCT06173570
  • -11.2% vs 0% 3 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
  • -7.5% vs 0% 1 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570

3-point MACE (% with event)

Enlicitide
—Not posted · NCT07216482
Laroprovstat
—Trial running · NCT06834932
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Enlicitide: 3 of 4 rows · Laroprovstat: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEnlicitideLaroprovstat
Dropout rate
—20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
3%
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
1%Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.6%30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
11.1%Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
5.9%30 mgb
NCT06173570 · Phase 2
show 3 more results
1.2%10 mg
NCT06173570 · Phase 2
4.7%3 mg
NCT06173570 · Phase 2
5.8%1 mg
NCT06173570 · Phase 2
Discontinued due to AEs
—20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
—
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
2.4%30 mgb
NCT06173570 · Phase 2
show 3 more results
0%10 mg
NCT06173570 · Phase 2
0%3 mg
NCT06173570 · Phase 2
1.2%1 mg
NCT06173570 · Phase 2
Serious AEs
9.9%20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
4.5%
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.6%30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
3.9%12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
1.3%6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
11.1%Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
1.2%30 mgb
NCT06173570 · Phase 2
show 3 more results
2.4%10 mg
NCT06173570 · Phase 2
2.4%3 mg
NCT06173570 · Phase 2
2.3%1 mg
NCT06173570 · Phase 2
Most frequent reported AEs
a
nasopharyngitis 9.4% (placebo 7.9%)
influenza 8.4% (placebo 8.9%)
accidental overdose 7.9% (placebo 4%)
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 9 more results
20 mg
accidental overdose 0%
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
30 mg
covid-19 5.3% (placebo 9.3%)
arthralgia 2.6% (placebo 1.3%)
nausea 2.6% (placebo 0%)
NCT05261126 · Phase 2 · registry result, not featured evidence
18 mg
covid-19 6.6% (placebo 9.3%)
nausea 5.3% (placebo 0%)
diarrhoea 3.9% (placebo 1.3%)
NCT05261126 · Phase 2 · registry result, not featured evidence
12 mg
dyspepsia 6.6% (placebo 1.3%)
arthralgia 5.3% (placebo 1.3%)
fatigue 3.9% (placebo 6.7%)
NCT05261126 · Phase 2 · registry result, not featured evidence
6 mg
covid-19 7.8% (placebo 9.3%)
diarrhoea 6.5% (placebo 1.3%)
dyspepsia 1.3% (placebo 1.3%)
NCT05261126 · Phase 2 · registry result, not featured evidence
dry mouth 12.5%
hypertension 12.5%
animal bite 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 12.5%
orthostatic hypotension 12.5%
dry mouth 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 0%
dry mouth 0%
hypertension 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 0%
dry mouth 0%
hypertension 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
30 mgb
hypertension 3.5% (placebo 5.8%)
NCT06173570 · Phase 2
show 3 more results
10 mg
hypertension 2.4% (placebo 5.8%)
NCT06173570 · Phase 2
3 mg
hypertension 2.4% (placebo 5.8%)
NCT06173570 · Phase 2
1 mg
hypertension 4.7% (placebo 5.8%)
NCT06173570 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for 8 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Enlicitide

LDL-C Less Than 70 and 50% Reduction 70.8% (n=202) vs 1% (n=101) placebo @ 24wk
responder rate · % of participants
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
81.2% (n=101) vs 2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Less Than 5.5 and 50 Pct Reduction 67.3% (n=202) vs 1% (n=101) placebo @ 24wk
responder rate · % of participants
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
78.2% (n=101) vs 2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Goal Attainment 90.8% (n=76) vs 9.3% (n=75) placebo @ 8wk30 mg
responder rate · % of participants
NCT05261126 · Phase 2 · registry result, not featured evidence
show 3 more results
90.8% (n=76) vs 9.3% (n=75) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
85.5% (n=76) vs 9.3% (n=75) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
80.5% (n=77) vs 9.3% (n=75) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence

Laroprovstat

Total Cholesterol -27.06% (n=85) vs 2.29% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-26.9% (n=85) vs 1.73% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-24.84% (n=84) vs 2.29% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-24.54% (n=84) vs 1.73% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-20.09% (n=85) vs 2.29% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-19.8% (n=85) vs 1.73% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-18.93% (n=86) vs 2.29% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-18.23% (n=86) vs 1.73% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
HDL-C 4.66% (n=85) vs 3.65% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
4.65% (n=85) vs 3.11% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
1.97% (n=84) vs 3.65% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
2.17% (n=84) vs 3.11% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
4.03% (n=85) vs 3.65% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
3.66% (n=85) vs 3.11% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
0.12% (n=86) vs 3.65% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
0.8% (n=86) vs 3.11% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Triglycerides -0.44% (n=85) vs 9.56% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-0.83% (n=85) vs 9.04% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
1.93% (n=84) vs 9.56% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
1.72% (n=84) vs 9.04% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
2.9% (n=85) vs 9.56% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.17% (n=85) vs 9.04% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
3.06% (n=86) vs 9.56% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
2.81% (n=86) vs 9.04% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
VLDL-C 0.46% (n=85) vs 7.19% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
0.42% (n=85) vs 6.74% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
2.21% (n=84) vs 7.19% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
1.77% (n=84) vs 6.74% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
4.02% (n=85) vs 7.19% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.67% (n=85) vs 6.74% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
1.13% (n=86) vs 7.19% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
0.81% (n=86) vs 6.74% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Apo A1 5.72% (n=85) vs 4.46% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
5.55% (n=85) vs 3.82% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
3.61% (n=84) vs 4.46% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
3.79% (n=84) vs 3.82% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
3.25% (n=85) vs 4.46% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.89% (n=85) vs 3.82% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
1.67% (n=86) vs 4.46% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
2.52% (n=86) vs 3.82% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Remnant Cholesterol -18.31% (n=77) vs -5% (n=80) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 3 more results
-22.95% (n=79) vs -5% (n=80) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-8.33% (n=75) vs -5% (n=80) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-9.09% (n=75) vs -5% (n=80) placebo @ 12wk1 mg
NCT06173570 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enlicitide's landscape · Laroprovstat's landscape